FDA Draft Guidance Will Aim To Increase CLIA Waiver Flexibility
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to release a CLIA waiver draft guidance by year end, according to the Office of In Vitro Diagnostic Devices Evaluation & Safety
You may also be interested in...
Long-Awaited CLIA Draft Guidance Offers Some Leeway For Study Design
FDA's CLIA waiver application draft guidance could offer test sponsors added flexibility in designing clinical studies
Long-Awaited CLIA Draft Guidance Offers Some Leeway For Study Design
FDA's CLIA waiver application draft guidance could offer test sponsors added flexibility in designing clinical studies
CLIA-Waived Test Market Increasing As Public Health Concerns Loom
Rapid growth in the adoption of CLIA-waived laboratory tests is causing some unease regarding appropriate use of the tests